ECM
GILD icon

EII Capital Management’s Gilead Sciences GILD Stock Holding History

EII Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-29,895
Closed -$2.14M – 235
2017
Q4 		$2.14M Hold
29,895
– – 0.91% 34
2017
Q3 		$2.42M Sell
29,895
-4,905
-14% -$375K 0.91% 36
2017
Q2 		$2.46M Buy
+34,800
New +$2.32M 0.83% 46

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EII Capital Management's GILD Position: Q1 2018 in Review

EII Capital Management sold out of Gilead Sciences (GILD) in Q1 2018, closing a stake of 29,895 shares — an estimated $2.14M sold.

EII Capital Management first reported a position in GILD in Q2 2017 and held it in 3 quarters. The position peaked at $2.46M in Q2 2017. 1,563 funds tracked by Wall St. Rank hold GILD as of Q1 2018.

  • EII Capital Management reported no remaining Gilead Sciences position as of Q1 2018 after selling out during the quarter.
  • EII Capital Management sold 29,895 Gilead Sciences shares in Q1 2018, an estimated $2.14M.
  • EII Capital Management first reported a position in Gilead Sciences in Q2 2017 and held it in 3 quarters.
  • EII Capital Management's Gilead Sciences position peaked at $2.46M in Q2 2017.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2018.

Based on EII Capital Management's 13F filing for Q1 2018, filed 14 May 2018.